← All trials
NCT06015737
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2023
- Primary completion
- Mar 25, 2026
- Completion date
- Dec 16, 2026
- First posted
- Aug 29, 2023
- Last posted
- Sep 22, 2023
- Enrollment
- 230
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- ParexelCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.